Boteng Co., Ltd. announced that Suzhou Boteng Biopharmaceutical Co., Ltd., a second-tier holding subsidiary of the company, recently obtained a “Pharmaceutical Production License” issued by the Jiangsu Drug Administration, which is valid until July 26, 2031. The license indicates that Suzhou Boteng has the compliance qualification to undertake commercial contract production of cell and gene therapy products, which is conducive to promoting the development of the company's cell and gene therapy CDMO business. Obtaining a “Pharmaceutical Production License” this time is not expected to have a significant impact on the company's 2026 performance.

Boteng Co., Ltd. announced that Suzhou Boteng Biopharmaceutical Co., Ltd., a second-tier holding subsidiary of the company, recently obtained a “Pharmaceutical Production License” issued by the Jiangsu Drug Administration, which is valid until July 26, 2031. The license indicates that Suzhou Boteng has the compliance qualification to undertake commercial contract production of cell and gene therapy products, which is conducive to promoting the development of the company's cell and gene therapy CDMO business. Obtaining a “Pharmaceutical Production License” this time is not expected to have a significant impact on the company's 2026 performance.